Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ebola Hemorrhagic Fever
Research findings from Emory University update understanding of ebola hemorrhagic fever
March 18th, 2009
"Ebola virus-like particles (VLPs) were produced in insect cells using a recombinant baculovirus expression system and their efficacy for protection against Ebola virus infection was investigated. Two immunizations with 50 mu g Ebola VLPs (high dose) induced a high level of antibodies against Ebola GP that exhibited strong neutralizing activity against GP-mediated virus infection and conferred complete protection of vaccinated mice against lethal challenge by a high dose of mouse-adapted Ebola virus," investigators in the United States report. "In contrast, two immunizations with 10 mu g Ebola VLPs (low dose) induced 5-fold lower levels of antibodies against GP and...
Source: Vaccine Weekly (2009-03-18)
|
